A Phase 2 interventional study of PVX-410 in Metastatic Triple-Negative Breast Carcinoma, sponsored by OncoPep, Inc.. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-20.
Sponsored by OncoPep, Inc. · Phase 2, Interventional, and Treatment
Evaluating the combination of the investigational, multi-peptide cancer vaccine PVX-410 in combination with pembrolizumab and chemotherapy in treatment naive patients with metastatic, triple negative breast cancer who are PDL1 and HLA A2 positive.
1,163 studies on the registry are indexed under Triple Negative Breast Neoplasms; 447 are open to participants now.
This study's planned enrollment of 53 is below the median of 61 across 1,001 interventional studies indexed under Triple Negative Breast Neoplasms.
Browse Triple Negative Breast Neoplasms studies →OncoPep, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- HLA A2 Positive PDL1 Positive Treatment naive, triple negative breast cancer
Exclusion Criteria:
-
Drug: PVX-410
PVX-410 in combination with pembrolizumab and chemotherapy
Progression Free Survival
Time frame: 8 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410
Triple Negative Breast Neoplasms →
OncoPep, Inc.